Literature DB >> 23658062

Optimization of triazine nitriles as rhodesain inhibitors: structure-activity relationships, bioisosteric imidazopyridine nitriles, and X-ray crystal structure analysis with human cathepsin L.

Veronika Ehmke1, Edwin Winkler, David W Banner, Wolfgang Haap, W Bernd Schweizer, Matthias Rottmann, Marcel Kaiser, Céline Freymond, Tanja Schirmeister, François Diederich.   

Abstract

The cysteine protease rhodesain of Trypanosoma brucei parasites causing African sleeping sickness has emerged as a target for the development of new drug candidates. Based on a triazine nitrile moiety as electrophilic headgroup, optimization studies on the substituents for the S1, S2, and S3 pockets of the enzyme were performed using structure-based design and resulted in inhibitors with inhibition constants in the single-digit nanomolar range. Comprehensive structure-activity relationships clarified the binding preferences of the individual pockets of the active site. The S1 pocket tolerates various substituents with a preference for flexible and basic side chains. Variation of the S2 substituent led to high-affinity ligands with inhibition constants down to 2 nM for compounds bearing cyclohexyl substituents. Systematic investigations on the S3 pocket revealed its potential to achieve high activities with aromatic vectors that undergo stacking interactions with the planar peptide backbone forming part of the pocket. X-ray crystal structure analysis with the structurally related enzyme human cathepsin L confirmed the binding mode of the triazine ligand series as proposed by molecular modeling. Sub-micromolar inhibition of the proliferation of cultured parasites was achieved for ligands decorated with the best substituents identified through the optimization cycles. In cell-based assays, the introduction of a basic side chain on the inhibitors resulted in a 35-fold increase in antitrypanosomal activity. Finally, bioisosteric imidazopyridine nitriles were studied in order to prevent off-target effects with unselective nucleophiles by decreasing the inherent electrophilicity of the triazine nitrile headgroup. Using this ligand, the stabilization by intramolecular hydrogen bonding of the thioimidate intermediate, formed upon attack of the catalytic cysteine residue, compensates for the lower reactivity of the headgroup. The imidazopyridine nitrile ligand showed excellent stability toward the thiol nucleophile glutathione in a quantitative in vitro assay and fourfold lower cytotoxicity than the parent triazine nitrile.
Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23658062     DOI: 10.1002/cmdc.201300112

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  13 in total

Review 1.  Urea-aromatic interactions in biology.

Authors:  Shampa Raghunathan; Tanashree Jaganade; U Deva Priyakumar
Journal:  Biophys Rev       Date:  2020-02-17

2.  Synthesis of Symmetric and Unsymmetric Secondary Amines from the Ligand-Promoted Ruthenium-Catalyzed Deaminative Coupling Reaction of Primary Amines.

Authors:  Pandula T Kirinde Arachchige; Hanbin Lee; Chae S Yi
Journal:  J Org Chem       Date:  2018-04-24       Impact factor: 4.354

3.  Discovery of covalent enzyme inhibitors using virtual docking of covalent fragments.

Authors:  Sandipan Roy Chowdhury; Steven Kennedy; Kai Zhu; Rama Mishra; Patrick Chuong; Alyssa-Uyen Nguyen; Stefan G Kathman; Alexander V Statsyuk
Journal:  Bioorg Med Chem Lett       Date:  2018-11-09       Impact factor: 2.823

4.  Development of a New Antileishmanial Aziridine-2,3-Dicarboxylate-Based Inhibitor with High Selectivity for Parasite Cysteine Proteases.

Authors:  Caroline Schad; Ulrike Baum; Benjamin Frank; Uwe Dietzel; Felix Mattern; Carlos Gomes; Alicia Ponte-Sucre; Heidrun Moll; Uta Schurigt; Tanja Schirmeister
Journal:  Antimicrob Agents Chemother       Date:  2015-11-23       Impact factor: 5.191

5.  Discovery and Optimization of Triazine Nitrile Inhibitors of Toxoplasma gondii Cathepsin L for the Potential Treatment of Chronic Toxoplasmosis in the CNS.

Authors:  Jeffery D Zwicker; David Smith; Alfredo J Guerra; Jacob R Hitchens; Nicole Haug; Steve Vander Roest; Pil Lee; Bo Wen; Duxin Sun; Lu Wang; Richard F Keep; Jianming Xiang; Vern B Carruthers; Scott D Larsen
Journal:  ACS Chem Neurosci       Date:  2020-02-18       Impact factor: 4.418

6.  Naphthoquinones as Covalent Reversible Inhibitors of Cysteine Proteases-Studies on Inhibition Mechanism and Kinetics.

Authors:  Philipp Klein; Fabian Barthels; Patrick Johe; Annika Wagner; Stefan Tenzer; Ute Distler; Thien Anh Le; Paul Schmid; Volker Engel; Bernd Engels; Ute A Hellmich; Till Opatz; Tanja Schirmeister
Journal:  Molecules       Date:  2020-04-28       Impact factor: 4.411

Review 7.  Cysteine proteases in protozoan parasites.

Authors:  Jair L Siqueira-Neto; Anjan Debnath; Laura-Isobel McCall; Jean A Bernatchez; Momar Ndao; Sharon L Reed; Philip J Rosenthal
Journal:  PLoS Negl Trop Dis       Date:  2018-08-23

8.  Crystal structure, Hirshfeld surface analysis and DFT studies of 6-bromo-3-(12-bromo-dodec-yl)-2-(4-nitro-phen-yl)-4H-imidazo[4,5-b]pyridine.

Authors:  Zainab Jabri; Karim Jarmoni; Tuncer Hökelek; Joel T Mague; Safia Sabir; Youssef Kandri Rodi; Khalid Misbahi
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2020-04-21

Review 9.  COVID-19: Drug Targets and Potential Treatments.

Authors:  Carmen Gil; Tiziana Ginex; Inés Maestro; Vanesa Nozal; Lucía Barrado-Gil; Miguel Ángel Cuesta-Geijo; Jesús Urquiza; David Ramírez; Covadonga Alonso; Nuria E Campillo; Ana Martinez
Journal:  J Med Chem       Date:  2020-06-26       Impact factor: 7.446

10.  New Cysteine Protease Inhibitors: Electrophilic (Het)arenes and Unexpected Prodrug Identification for the Trypanosoma Protease Rhodesain.

Authors:  Philipp Klein; Patrick Johe; Annika Wagner; Sascha Jung; Jonas Kühlborn; Fabian Barthels; Stefan Tenzer; Ute Distler; Waldemar Waigel; Bernd Engels; Ute A Hellmich; Till Opatz; Tanja Schirmeister
Journal:  Molecules       Date:  2020-03-23       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.